Konference: 2015 20th Congress of the European Hematology Association - účast ČR
Kategorie: Maligní lymfomy a leukémie
Téma: Poster
Číslo abstraktu: P566
Autoři: Prof. Dr. med. Hartmut Döhner (Doehner); MD Dominik Selleslag; Prof. MD James D. Cavenagh; Prof. John Francis Seymour, MD, PhD, MBBS, FRACP; MD Mark D. Minden, PhD, FRCPC; prof. Christian Recher; Prof.MD Giovanni Martinelli; prof. MUDr. Jiří Mayer, CSc.; MD Patricia Font López; MD Hee-Je Kim, PhD; Wen-Chien Chou; Andrea Kew; MD Yoo Hong Min, PhD; Stev Songer; Lela Lucy; MD C.L. Beach; Herve Dombret
Background
There is no universally accepted approach to AML treatment (Tx) for
older pts. IC is recommended for pts aged ≥60 years with favorable
prognostic features (NCCN guidelines, 2014). However, many older
pts can not tolerate IC. Such pts often receive low-dose cytarabine
(LDAC), which is associated with a median OS of only ~5 months
(Burnett, Cancer, 2007; Kantarjian, JCO, 2012).
There is an unmet need for tolerable Tx options that prolong OS to
a similar or greater extent than IC. The phase 3, randomized
AZA-AML-001 study compared AZA with conventional care regimens
(CCR) in older pts with AML. Before randomization, pts were
preselected to receive 1 of 3 CCR per investigator choice of
preferred Tx option: IC, LDAC, or best supportive care only. Pts
were then randomized to receive AZA or CCR and received their
preselected Tx.
Aims
To compare OS and clinical outcomes with AZA vs IC in the subgroup
of pts in AZA-AML-001 preselected to receive IC before
randomization.
Methods
Pts aged ≥65 years with newly diagnosed de novo or
secondary AML (>30% bone marrow [BM] blasts) and ECOG PS 0-2,
WBC ≤15x109/L, and intermediate- or poor-risk
cytogenetics were enrolled. Pts received IC (cytarabine IV x7days
(d) + an anthracycline IV x3d, with ≤2 subsequent cycles) or AZA
(75 mg/m2/d SC x7d/28d cycle). OS and 1-year survival
were estimated using Kaplan-Meier methods. OS was compared between
Tx groups by log-rank test. Hazard ratios (HRs) and 95% CI are from
an unstratified Cox proportional hazards model. Rates and durations
of complete remission (CR) and CR with incomplete blood count
recovery (CRi) (IWG 2003), and RBC transfusion independence (TI) in
pts transfusion-dependent at baseline, were assessed. Rates of
grade 3-4 treatment-emergent adverse events (TEAEs), defined as new
or worsening AEs during Tx, were assessed. To account for
differences in Tx exposure, TEAE incidence rates (IR) per 100
pt-years of Tx exposure are reported.
Results
Of all pts in AZA-AML-001 (N=488), 87 (18%) were preselected to
receive IC (AZA n=43, IC n=44). Median number of Tx cycles of AZA
was 8 (range 1–24) and of IC was 2 (1–3). At baseline in the AZA
and IC groups, median ages were 71 yrs (AZA range 65–79, CCR
65–81); 16% and 18% of pts, respectively, had ECOG PS of 2; median
BM blasts were 72% (7-100%) and 70% (6–100%); median WBC count was
3.8x109/L (1-15) and 2.2 x109/L (1-90); and
35% and 34% of pts had poor-risk cytogenetics. Median OS was
comparable in the AZA and IC groups: 13.3 vs 12.2 months,
respectively (HR=0.85 [95% CI 0.52, 1.38], p=0.5032)
(Figure). One-year survival with AZA was 55.8%
(95% CI 39.8%, 69.1%) vs 50.9% (35.2%, 64.6%) with IC (Δ4.9%; 95%
CI -16.2%, 26.0%). In the AZA and IC groups, respectively, 30% and
36% of pts attained CR, and 12% and 11% achieved CRi. Median
durations of CR+CRi in the AZA and IC groups were 17.3 (95% CI 3.7,
not reached) and 19.8 (8.2, 26.3) months, respectively. RBC TI
rates with AZA vs IC were 57% vs 35%, respectively. Proportions of
pts with grade 3-4 TEAEs and [IRs] in the AZA and IC groups,
respectively, were: anemia 12% vs 14% [14 vs 45]; neutropenia 30%
vs 33% [37 vs 99]; febrile neutropenia 33% vs 31% [40 vs 92];
thrombocytopenia 23% vs 21% [29 vs 64]; and (any) infections 49% vs
50% [60 vs 149].
Summary
AZA and IC were associated with comparable OS, 1-year survival, and
rate and duration of remission in these older pts with AML. AZA was
better tolerated than IC, with lower incidence rates of hematologic
TEAEs and infections. AZA may be a good option for older pts with
AML who are fit for IC but choose not to undergo high-intensity
Tx.
Keyword(s): Acute myeloid leukemia, Induction
chemotherapy, Survival
Datum přednesení příspěvku: 13. 6. 2015